Cargando…
Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England
RATIONALE, AIMS, AND OBJECTIVES: Several novel oral anticoagulants (NOACs) are licensed for atrial fibrillation (AF) treatment in the United Kingdom. We describe the incidence and mortality from ischaemic stroke and major bleeding in non‐valvular atrial fibrillation (NVAF) patients in England, inclu...
Autores principales: | Bakhai, Ameet, Petri, Hans, Vahidnia, Farnaz, Wolf, Cyrill, Ding, Yingjie, Foskett, Nadia, Sculpher, Mark |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7891325/ https://www.ncbi.nlm.nih.gov/pubmed/32314853 http://dx.doi.org/10.1111/jep.13400 |
Ejemplares similares
-
Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores
por: Proietti, Marco, et al.
Publicado: (2016) -
Burden of major gastrointestinal bleeding among oral anticoagulant-treated non-valvular atrial fibrillation patients
por: Deitelzweig, Steven, et al.
Publicado: (2021) -
Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study
por: Al-Najar, Mahasen, et al.
Publicado: (2023) -
Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants
por: Chang, Kuo-Hsuan, et al.
Publicado: (2022) -
Metabolomic and Proteomic Analyses of Persistent Valvular Atrial Fibrillation and Non-Valvular Atrial Fibrillation
por: Hu, Bo, et al.
Publicado: (2021)